Concepedia

Marilena Gallotta

MG

10

Publications

820

Citations

10

H-Index

2010

Active since

Affiliations

Novartis (Italy)(Current)

Dynavax Technologies (United States)

Karolinska Institutet

Novartis (Switzerland)

Karolinska University Hospital

Marilena Gallotta is an author at Novartis (Italy) specializing in infection control, vaccine development, and medicine.

ORCID

Top concepts

Publications per year

2010–2021

10

Publications

10

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 <sup>+</sup> T cells

Shu Wang, Jose Campos, Marilena Gallotta et al. · Proceedings of the National Academy of Sciences · 2016 · 221 citations · Full text

The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination

Maria Vono, Marianna Taccone, Paola Caccin et al. · Proceedings of the National Academy of Sciences · 2013 · 155 citations · Full text

Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case

Giuliano Bensi, Marirosa Mora, Giovanna Tuscano et al. · Molecular & Cellular Proteomics · 2012 · 135 citations · Full text

, , +17

Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate

Anna Kabanova, Immaculada Margarit, Francesco Berti et al. · Vaccine · 2010 · 92 citations

, , +8

Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay

Marilena Gallotta, Hikmat Assi, Émilie Degagné et al. · Cancer Research · 2018 · 82 citations · Full text

Rows per page

1–5 of 10